Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels

Belloni, Benedetta; Ziai, Mahzad; Lim, Annick; Lemercier, Brigitte; Sbornik, M.; Weidinger, Stephan; Andrés, Christian; Schnopp, Christina; Ring, Johannes; Hein, Rüdiger; Ollert, Markus; Mempel, Martin

doi:10.1016/j.jaci.2007.08.060

Cited by 139 publications

(112 citation statements)

References 9 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…It seems that Xolair could be effective in decreasing IgE levels in different doses and durations of the treatment, although, the decrease of IgE level is not important on its own. Some studies showed that the decrease of IgE did not associate with clinical resolutions (9,11). Clinical manifestations improved in all of the studies (3,(8)(9)(10)(11)(12)(13)(14) except one, other researches had no control group.…”

Section: Discussionmentioning

confidence: 92%

“…These articles include 4 purely about children, 3 about both the child and adult, and associated with one case report. Two studies included both children and adult population; we could not distinguish how many children were under the age of 21 years (8,9). Except the 2 cases with moderate severity, all of them had severe AD (10).…”

Section: Resultsmentioning

confidence: 99%

“…AD were associated with other allergic disorders such as asthma and allergic rhinitis (AR) in all patients (Table 1). All patients had taken Xolair subcutaneously (SC) (3,(8)(9)(10)(11)(12)(13)(14).…”

Section: Resultsmentioning

confidence: 99%

“…Cases had taken the drug for 2 or 4 weeks SC. The drug dosage was different in these studies, from 150 mg, 150 mg to 375 mg, 225 mg to 375 mg, and 300 mg to 375 mg (9,(11)(12)(13). The reason for this difference is because of the difference in weight of the patients and baseline IgE.…”

Section: Discussionmentioning

confidence: 96%

“…It seems that the dose of the drug could be adjusted based on the patient's response. The duration of treatment was different from 12 weeks, 20 weeks, 24 weeks, and 12 to 67 months (9,(11)(12)(13). Serum IgE level decreased in 100% of the studies (3,(8)(9)(10)(11)(12)(13)(14).…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article

Ghaffari

2017

J Pediatr Rev

View full text Add to dashboard Cite

Context: Atopic dermatitis is a chronic skin disease in children. The prevalence of eczema is up to 30% in the world. Omalizumab (Xolair) is a monoclonal antibody that blocks the serum IgE. The aim of this study is to review the effect of Xolair in children with atopic dermatitis. Evidence Acquisition: The data was searched in PubMed, Scopus, and Embase with keywords: atopic dermatitis, eczema, children, pediatrics, Xolair, and Omalizumab. The inclusion criteria included articles related to use of Xolair in children with atopic dermatitis, under the age of 20 years old, as well a both full text and brief articles. The exclusion criteria were purely adult cases who had taken systemic immunosuppressive drugs and abstract article. There was no time limitation for our search. Results: After evaluating all data and a total of 124 searched articles, we found 8 eligible articles for this review. All of them had severe atopic dermatitis except 2 cases, which had moderate severity. Serum IgE level was increased in all patients. Only one of those studies included a control group. All patients were associated with other allergic disorders such as asthma and allergic rhinitis. Conclusions: Omalizumab (Xolair) is a safe drug, which decreases serum IgE level, scoring atopic dermatitis, as well as clinical manifestations in all of severe atopic dermatitis. However, in order to approve it, we need future clinical trial studies with control group.

show abstract